Zobrazeno 1 - 10
of 87
pro vyhledávání: '"Derek H. Tang"'
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-12 (2019)
Abstract Background The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Me
Externí odkaz:
https://doaj.org/article/a41a4921f0444c218266b7e94024fd8f
Autor:
Nina Galipeau, Brittany Klooster, Meaghan Krohe, Derek H. Tang, Dennis A. Revicki, David Cella
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-12 (2019)
Abstract Background Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. T
Externí odkaz:
https://doaj.org/article/91841a67a89a42e0abdb055e8b225bc4
Autor:
Elizabeth J. Anderson, Lea E. Mollon, Joni L. Dean, Terri L. Warholak, Ayal Aizer, Emma A. Platt, Derek H. Tang, Lisa E. Davis
Publikováno v:
International Journal of Breast Cancer, Vol 2020 (2020)
PIK3CA mutation frequency varies among breast cancer (BC) subtypes. Recent evidence suggests combination therapy with the PI3K inhibitor (PI3Ki) alpelisib and endocrine therapy (ET) improves response rates and progression-free survival (PFS) in PIK3C
Externí odkaz:
https://doaj.org/article/5c845fb500a7445eb1ffd902fb2a04f9
Autor:
Ayal A. Aizer, Terri L. Warholak, Joni L. Dean, Lea Mollon, Derek H. Tang, Elizabeth Anderson, Lisa E. Davis, Emma Platt
Publikováno v:
Clinical Breast Cancer. 20:e232-e243
PIK3CA mutations may have prognostic value for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer, representing an important potential target for systemic therapy. Prognostic and predict
Autor:
Nicholas J. Vogelzang, Austin Poole, Wei Gao, Xiting Cao, Lixian Jin, Derek H. Tang, Barbara Ratto, Elyse Swallow, Shoba Ravichandran
Publikováno v:
Clinical Genitourinary Cancer. 18:e37-e45
Introduction In the first-line (1L) setting, pazopanib (PAZ) has been recommended by the National Comprehensive Cancer Network for the treatment of advanced renal cell carcinoma (aRCC). In 2018, immuno-oncology (IO) therapy became a commonly used 1L
Publikováno v:
Journal of Health Economics and Outcomes Research, Vol 3, Iss 2 (2015)
**Background:** Until recently, the lack of clinical outcomes information for rheumatoid arthritis (RA) in administrative claims databases limited their use in comparative effectiveness research. A validated claims-based algorithm has been developed
Externí odkaz:
https://doaj.org/article/880514a23f80480fb15ab848ca6dfb0a
Autor:
Derek H. Tang, Christopher Zacker, Anand A. Dalal, Joseph Biskupiak, Diana I. Brixner, Gary M. Oderda
Publikováno v:
Journal of Managed Care & Specialty Pharmacy. 25:859-866
Discarding unused drugs after dose changes or discontinuation can significantly affect pharmacy budgets. This is especially concerning for expensive oncology agents. However, few economic studies account for drug wastage, providing an inaccurate esti
Autor:
Nina Galipeau, Dennis A. Revicki, Derek H. Tang, Brittany Klooster, Meaghan Krohe, David Cella
Publikováno v:
Health and Quality of Life Outcomes, Vol 17, Iss 1, Pp 1-12 (2019)
Health and Quality of Life Outcomes
Health and Quality of Life Outcomes
Background The purpose of this study is to evaluate the content validity of the National Comprehensive Cancer Network – Functional Assessment of Cancer Therapy – Breast Cancer Symptom Index (NFBSI-16) and the Patient-Reported Outcomes Measurement
Autor:
Meaghan Krohe, David Cella, Brittany Klooster, Nina Galipeau, Derek H. Tang, Dennis A. Revicki
Publikováno v:
Journal of Patient-Reported Outcomes, Vol 3, Iss 1, Pp 1-12 (2019)
Journal of Patient-Reported Outcomes
Journal of Patient-Reported Outcomes
Background Patients with breast cancer experience a variety of disease symptoms and treatment-related side effects that can adversely affect functioning. The breast cancer experience may differ across disease stages and biomarker subtypes. This study
Autor:
Derek H. Tang, Aditya Bardia, Ayal A. Aizer, Nicole Princic, William J. Johnson, David M. Smith
Publikováno v:
Current Medical Research and Opinion. 35:73-80
Objective: To identify systemic treatment in the real-world following treatment with a cyclin-dependent kinase 4/6 inhibitor (CDKi) among post-menopausal women with hormone receptor positive, human...